Colorectal Cancer Therapeutics Market to grow with a CAGR of 4.20 %
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Colorectal Cancer Therapeutics Market through 2029
According
to TechSci Research report, “Global Colorectal Cancer Therapeutics Market
Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, Global Colorectal Cancer
Therapeutics Market has valued at USD 11.10 billion in 2023 and is anticipated
to witness an impressive growth in the forecast period with a CAGR of 4.20%
through 2029. This can be due to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market. Advances in
diagnostic technologies have significantly improved the early detection,
diagnosis, and monitoring of colorectal cancer. These technologies have a
profound impact on the field of colorectal cancer therapeutics. Colonoscopy and
Flexible Sigmoidoscopy: These endoscopic procedures have become more precise
and less invasive, allowing for the direct visualization and biopsy of
colorectal tumors, as well as the removal of polyps before they become
cancerous. CT Colonography (Virtual Colonoscopy) is a non-invasive imaging
technique that uses computed tomography to produce detailed 3D images of the
colon, aiding in the detection of polyps and tumors. MRI scans can provide
detailed images of the colon and rectum, helping in the staging of colorectal
cancer and the assessment of tumor extent. Stool DNA Testing, such as the
Cologuard test, detects DNA changes associated with colorectal cancer in stool
samples. They are non-invasive and can be used for early detection. Blood
tests, such as the carcinoembryonic antigen (CEA) test, help in monitoring
cancer progression and response to treatment. Liquid biopsies involve the
analysis of circulating tumor DNA (ctDNA) in the bloodstream. They can detect
genetic mutations, alterations, and the presence of cancer, offering a
non-invasive means of early diagnosis and treatment monitoring.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Global Colorectal Cancer Therapeutics Market”
In January 2023, Takeda has announced an exclusive
licensing agreement with HUTCHMED (China) Limited and its subsidiary, HUTCHMED
Limited, for the continued development and commercialization of fruquintinib
outside of mainland China, Hong Kong, and Macau. Fruquintinib, which received
approval in China in 2018, is a potent inhibitor of vascular endothelial growth
factor receptors (VEGFR) -1, 2, and 3. It is orally administered and holds
promise for the treatment of refractory metastatic colorectal cancer (CRC)
across different biomarker statuses. Notably, positive results from the
FRESCO-2 Phase 3 clinical trial, presented at the European Society for Medical
Oncology (ESMO) Congress in September 2022, demonstrated that fruquintinib
improved overall survival in patients with metastatic CRC and exhibited a
generally well-tolerated safety profile.
Immunotherapy
response variability is a challenge in the global colorectal cancer
therapeutics market. The variability in patient response to immunotherapy in
the context of colorectal cancer is influenced by several factors, and it
presents challenges for treatment efficacy. Colorectal cancer is characterized
by significant tumor heterogeneity, with various genetic and molecular
subtypes. Not all tumors have the same immunogenicity, and this can lead to
differing responses to immunotherapies. While some colorectal cancer patients
respond well to immunotherapy, the identification of reliable predictive
biomarkers for treatment response, such as PD-L1 expression or MSI-high status,
is not always straightforward. Not all patients with these biomarkers respond,
and some without them may still benefit. The composition of the tumor
microenvironment, including the presence of immune cells, the immunosuppressive
effect of certain cell types, and the expression of immune checkpoint proteins,
can influence treatment response. Tumors with an immune-suppressed
microenvironment may be less responsive to immunotherapies. A significant
portion of colorectal cancer cases is microsatellite stable, and they often
exhibit a reduced response to immunotherapies compared to MSI-high tumors. Some
tumors develop resistance to immunotherapies over time, limiting the duration
of response and leading to treatment failure.
The Global Colorectal Cancer Therapeutics Market is
segmented based on Drug Class, and by region
Based on the Drug Class, Global Colorectal Cancer
Therapeutics Market is segmented into Chemotherapy,
Immunotherapy, and others. Chemotherapy is a cancer treatment that uses
drugs to stop the growth and spread of cancer cells. It is one of the most
widely used and effective methods for treating various types of cancer.
Chemotherapy is used to target and destroy rapidly dividing and multiplying
cancer cells. It can be employed as the primary treatment for cancer,
particularly when the cancer has spread or is in advanced stages, or it can be
used in combination with other treatments, such as surgery or radiation
therapy. Chemotherapy can have side effects because it affects both healthy and
cancerous cells. Common side effects may include nausea, vomiting, fatigue,
hair loss, anemia, lowered immunity, and digestive issues. The severity and
specific side effects can vary depending on the drugs used and the individual's
tolerance. The duration of chemotherapy treatment varies based on the type and
stage of cancer. It may involve several cycles of treatment, each followed by a
rest period to allow the body to recover.
Based on Region, North America held the largest share in the Global Colorectal Cancer Therapeutics
Market. There are well-established colorectal cancer awareness and
screening programs in North America. Efforts to promote early detection and
regular screenings have contributed to a higher proportion of patients being
diagnosed at earlier stages, when treatments are more effective. North America
is home to a significant portion of the global pharmaceutical industry. Major
pharmaceutical companies based in the United States and Canada invest heavily
in research and development for cancer therapeutics, including colorectal
cancer treatments. Governments and federal agencies in North America provide
substantial support and funding for cancer research, including colorectal
cancer. This support helps drive advancements in treatment options. North
American companies often play a leadership role in the global pharmaceutical
and biotechnology markets. This allows them to influence and shape the global
colorectal cancer therapeutics market significantly.
Some
of the major companies operating in the Global
Colorectal Cancer Therapeutics Market include:
- Amgen,
Inc.
- Bayer
AG
- Bristol-Myers
Squibb Company
- Elli
and Lilly Co.
- Merck
& co., Inc.
- F.
Hoffmann-La Roche Ltd.
- Sanofi
SA
Download Free Sample Report
Customers can also request 10% free
customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for Colorectal Cancer
Therapeutics. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Colorectal Cancer Therapeutics Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Colorectal Cancer Therapeutics Market by Drug Class (Chemotherapy, Immunotherapy,
others), By Region, By Competition Forecast & Opportunities, 2019-2029F has evaluated
the future growth potential of Global Colorectal Cancer Therapeutics Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Colorectal Cancer Therapeutics Market.
Contact
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com